Hala El‐Zimaity

Hala El‐Zimaity

Auto-generated profile, based on publicly available information

Hala El‐Zimaity

Dynacare Laboratories Brampton ON Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2018 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
HEHala El-Zimaity
Hala El-Zimaity
WCWon-Tak Choi
Won-Tak Choi
GLGregory Y. Lauwers
Gregory Y. Lauwers
RRRobert Riddell
Robert Riddell

23 September 2011 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
PDF file
GFGary W. Falk
Gary W. Falk
BJBrian C. Jacobson
Brian C. Jacobson
RRRobert H. Riddell
Robert H. Riddell
JRJoel H. Rubenstein
Joel H. Rubenstein
HEHala El‐Zimaity
Hala El‐Zimaity
GNGerardo Nardone
Gerardo Nardone
Although the prevalence of Barrett's esophagus (BE) is rising no data exist for racial minorities on prevalence in the general population. Minorities have a lower prevalence than Caucasians, and yet age, smoking, abdominal obesity, and Helicobacter pylori are all risk factors. Metabolic changes induced by adipocytokines and the apparently strong association between obesity, central adiposity, and BE may lead to reconsideration of some aspects of the natural history of BE. There is lack of experimental evidence on acid sensitivity and BE, which is hyposensitive compared to esophageal reflux disease. Reactive nitrogen and oxygen species lead to impaired expression of tumor suppressor genes, which can lead to cancer development; thus, antioxidants may be protective. Gastroesophageal reflux disease may be considered an immune‐mediated disease starting at the submucosal layer; the cytokine profile of the mucosal immune response may explain the different outcome of gastroesophageal reflux.

31 December 2020 in Histopathology
Verified
Journal Article
Open access
PDF file
HEHala El‐Zimaity
Hala El‐Zimaity
RRRobert H Riddell
Robert H Riddell
In daily practice, the presence of inflammation in gastric biopsies prompts a mental algorithm, an early question being whether the lesion present is Helicobacter‐associated. If Helicobacter organisms are not found, then there is a further algorithm, governed by the predominant type of inflammatory cells present, and the presence of other features such as intraepithelial lymphocytosis, a subepithelial collagen band, granulomas, coexisting chronic inflammation, focality, and superimposed reactive changes including erosions and ulcers. Each of these generates its own differential diagnosis. If no inflammation is present, then the two major changes specifically looked for are the changes associated with hypergastrinaemia, by far the most common cause of which is treatment with proton pump inhibitors, and reactive changes. These may be present with and without accompanying inflammation, and, when the epithelial changes dominate, the term gastropathy is preferred. In this article, we present an approach to non‐Helicobacter inflammation and gastropathies.